CAH vs NUS
Cardinal Health Inc. and NU Skin Enterprises, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CAH | NUS |
|---|---|---|
| Revenue | $254.2B | $1.5B |
| Net income | $1.7B | $160.2M |
| Gross margin | 3.8% | 69.4% |
| Net margin | 0.7% | 10.8% |
| Return on equity | — | 22.0% |
| Diluted EPS | $7.23 | $3.18 |
| Dividend / share | $2.04 | — |
| Payout ratio | 28.6% | 7.4% |
| Free cash flow | $4.5B | $46.0M |
| Equity | $-2.9B | $805.2M |
| Net debt / equity | — | −0.02× |
| Current ratio | 0.88× | 2.08× |
| Revenue CAGR 5y | 9.4% | −10.5% |
| Profit CAGR 5y | 22.9% | −3.5% |
CAH bills 171.2× the revenue of NUS, and NUS keeps more of each dollar of revenue as profit (10.8% against 0.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | CAH | NUS |
|---|---|---|
| FY2025 | $254.2B | $1.5B |
| FY2024 | $222.6B | $1.7B |
| FY2023 | $226.8B | $2.0B |
| FY2022 | $205.0B | $2.2B |
| FY2021 | $181.3B | $2.7B |
| FY2020 | $162.5B | $2.6B |
| FY2019 | $152.9B | $2.4B |
| FY2018 | $145.5B | $2.7B |
| FY2017 | $136.8B | $2.3B |
| FY2016 | $130.0B | $2.2B |
Net income by year
Bottom line
| Fiscal year | CAH | NUS |
|---|---|---|
| FY2025 | $1.7B | $160.2M |
| FY2024 | $1.6B | $-146.6M |
| FY2023 | $852.0M | $8.6M |
| FY2022 | $330.0M | $104.8M |
| FY2021 | $-938.0M | $147.3M |
| FY2020 | $611.0M | $191.4M |
| FY2019 | $-3.7B | $173.6M |
| FY2018 | $1.4B | $121.9M |
| FY2017 | $256.0M | $129.4M |
| FY2016 | $1.3B | $143.1M |